Clinical Trial Update: Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial is evaluating the combination of enfortumab vedotin and pembrolizumab for cisplatin-eligible upper tract urothelial carcinoma and is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Upper Tract Urothelial Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Padcev (enfortumab vedotin)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Urothelial Carcinoma | Phase 2 | Status: RECRUITING